Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy

Basit Öğe Kaydı
dc.authoridBaysal, Mehmet/0000-0001-7681-4623
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authoridUmit, Elif/0000-0001-5589-3000
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.contributor.authorUmit, Elif G.
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorBas, Volkan
dc.contributor.authorAsker, Ismail
dc.contributor.authorKirkizlar, Onur
dc.contributor.authorDemir, Ahmet M.
dc.date.accessioned2024-06-12T11:08:55Z
dc.date.available2024-06-12T11:08:55Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose Multiple myeloma is a chronic, uncurable hematological cancer with the involvement of multiple organ systems. As a disease affecting older patients, the treatment of multiple myeloma should be based on individual patient characteristics. Polypharmacy is an increasing problem in the care of older patients and in patients with multiple myeloma, polypharmacy is almost inevitable. We aimed to evaluate the applicability of polypharmacy definitions and the relation of polypharmacy with disease outcomes in patients with multiple myeloma. Methods Eighty patients older than 65 years and diagnosed with multiple myeloma were retrospectively enrolled. Patient files, prescriptions, evaluations for polypharmacy were determined according to Beers and START/STOPP criteria. Outcomes were recorded from files in terms of fractures, autonomous neuropathy, and renal functions. Results Polypharmacy with >= 4 drugs was observed in 65 patients while polypharmacy with >= 5 drugs was observed in 51 patients. Autonomous neuropathy, polypharmacy with more than four or five medications, and use of multiple medications in the same category were related with poor ECOG performance status in women, while prolonged use of benzodiazepines and central nervous system (CNS) affecting drugs and inappropriate polypharmacy were more frequent in men with poor ECOG performance status. The majority of patients aged 75-84 years were observed to use inappropriate polypharmacy. Autonomous neuropathy and fall risk were observed to be significantly related with inappropriate polypharmacy. Conclusions Drugs affecting balance and perception should be reconsidered in patients with multiple myeloma.en_US
dc.identifier.doi10.1177/1078155219835303
dc.identifier.endpage50en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue1en_US
dc.identifier.pmid30890065en_US
dc.identifier.scopus2-s2.0-85063349451en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage43en_US
dc.identifier.urihttps://doi.org/10.1177/1078155219835303
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22605
dc.identifier.volume26en_US
dc.identifier.wosWOS:000501268400006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMyelomaen_US
dc.subjectPolypharmacyen_US
dc.subjectFall Risken_US
dc.subjectNeuropathyen_US
dc.subjectGeriatric Assessmenten_US
dc.subjectCriteriaen_US
dc.titlePolypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu